Full Year 2024 Results Key Financial Results Revenue: US$22.3m (down 12% from ...

Shares of Capricor Therapeutics (CAPR) are trading up by about 13% on Thursday noon after the company announced ...

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Capricor Therapeutics ...

Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) saw some unusual options trading on Thursday. Traders acquired ...

Capricor Therapeutics (CAPR) released expectation-beating results for the fourth quarter, sending the shares up over 5% in aftermarket trading.

Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease-- --Data Presented at the ...

Capricor Therapeutics, Inc.’s CAPR share price has surged by 17.51%, which has investors questioning if this is right time to ...

AlphaQuest LLC purchased a new position in Capricor Therapeutics Inc (NASDAQ:CAPR – Free Report) during the fourth quarter, ...

Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramiocel for the treatment of Duchenne ...

“2024 was a transformational year for Capricor and the patients we serve as we move closer to our goal of bringing the first cellular therapy to market for the treatment of Duchenne ...